Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Side Effects of AxitinibUnderstanding the possible side effects that may occur during treatment with axitinib can help patients enhance self-monitoring awareness and improve treatm···【more】
Article source：Captain MedicineRelease date：2026-03-26Recommended：32
Side Effects of TazemetostatAs a drug used for treating certain tumors, tazemetostat may cause varying degrees of side effects in some patients due to individual differences, while···【more】
Article source：Captain MedicineRelease date：2026-03-26Recommended：42
Larotrectinib may cause a range of side effects and adverse reactions, varying from mild to severe. Understanding these potential side effects is crucial for patients undergoing tr···【more】
Article source：Captain MedicineRelease date：2026-03-26Recommended：40
The specific treatment regimen for tazemetostat should be determined by a qualified physician based on the patient's condition, body weight, liver and kidney function, concomit···【more】
Article source：Captain MedicineRelease date：2026-03-26Recommended：36
Pirtobrutinib is a BTK inhibitor developed by Eli Lilly and Company in the United States. It was first approved by the U.S. Food and Drug Administration (FDA) on January 27, 2023.I···【more】
Article source：Captain MedicineRelease date：2026-03-25Recommended：45
During treatment with pirtobrutinib, some side effects may occur, and these effects vary from person to person. Before receiving pirtobrutinib treatment, patients need to thoroughl···【more】
Article source：Captain MedicineRelease date：2026-03-25Recommended：45
For Patients with Severe Renal Impairment(1). If the current dose is 200 mg once daily, reduce the pirtobrutinib dose to 100 mg once daily.(2). If the current dose is other than 20···【more】
Article source：Captain MedicineRelease date：2026-03-25Recommended：41
Pirtobrutinib is a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor developed by Eli Lilly in the United States. It was first approved by the U.S. FDA on Janu···【more】
Article source：Captain MedicineRelease date：2026-03-25Recommended：45
Enasidenib helps restore the normal differentiation of leukemia cells by inhibiting the activity of mutant IDH2 enzymes. During treatment, it may also affect the function of normal···【more】
Article source：Captain MedicineRelease date：2026-03-24Recommended：27
The dosage and administration of enasidenib must strictly follow medical advice and be conducted under the guidance of a qualified physician. Do not adjust the dose or stop taking ···【more】
Article source：Captain MedicineRelease date：2026-03-24Recommended：36
The use of tepotinib must strictly adhere to the principle of individualized treatment. The administration and dosage should be determined by a qualified physician based on the pat···【more】
Article source：Captain MedicineRelease date：2026-03-24Recommended：32
Side Effects of TepotinibPatients should schedule regular follow-ups during treatment with Tepotinib and closely monitor any changes in their physical condition. If symptoms such a···【more】
Article source：Captain MedicineRelease date：2026-03-24Recommended：32
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：2252025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4532024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：2312025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：2452025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：2242025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：2532025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2342025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：2162025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
